Parathyroid scintigraphy: first experiences with technetium (III)-99m-Q12.
We report the preliminary results of a prospective study demonstrating technetium(III)-99m furifosmin (Q12) uptake in histologically proven parathyroid adenomas. Scintigraphy was performed in 12 patients with hyperparathyroidism. Q12 correctly identified the parathyroid adenomas by focal prolonged tracer retention in ten of the 12 patients. In the two patients without localized tracer retention, no parathyroid adenoma could be identified surgically, either. The retention half-times ranged from 0.5 to 1.8 h (mean 1.27) in the parathyroid adenomas and from 0.3 to 1.2 h (mean 1.05) in the thyroid gland. Our preliminary results show that Q12 is a feasible, sensitive tracer for parathyroid scintigraphy. In comparison to sestamibi (MIBI) and tetrofosmin, Q12 displays short retention in the thyroid gland, which would seem rather advantageous. Further evaluation is needed to determine which among Q12, tetrofosmin and MIBI is most sensitive for the detection especially of small parathyroid adenomas, and which tracer properties will best reflect the degree of endocrine activity.
Aigner
R M
RM
Department of Radiology, University Hospital Graz, Austria.
Fueger
G F
GF
Wolf
G
G
D000236:Adenoma / Q000000981:diagnostic imaging*; D000328:Adult; D000368:Aged; D005240:Feasibility Studies; D005260:Female; D005663:Furans; D006801:Humans; D006961:Hyperparathyroidism / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D010282:Parathyroid Neoplasms / Q000000981:diagnostic imaging*; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi
D005663:Furans; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078496:technetium Tc 99m Q12; C078700:technetium tc-99m tetrofosmin; D017256:Technetium Tc 99m Sestamibi